NovaBay Pharmaceuticals to Distribute Zocular® Dry Eye Products
August 19 2021 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
pharmaceutical company focusing on commercializing Avenova for the
eye care market, announces an agreement with Okra Limited to
distribute their Zocular dry eye products alongside Avenova in
NovaBay’s physician-dispensed sales channel. Products sold under
the Zocular brand were developed by Okra Limited CEO Peter Pham,
MD, a board-certified ophthalmologist, and are all complementary to
Avenova. They are formulated with Zokrex™, a patented technology
with activated natural okra polysaccharide complexes, and are
designed to gently and effectively clear Demodex, scurf and residue
from eyelids.
“We’ve been searching for additional dry eye products to add to
our established sales channels for some time. The Zocular product
line is ideal for eyecare specialists seeking effective tools to
treat their patients’ dry eye and is a perfect complement to
Avenova,” said Justin Hall, NovaBay CEO. “Zocular products are
formulated with a novel, powerful technology to address
inflammation at the eyelid margin. Avenova is the only lid and lash
antimicrobial spray to be clinically proven to reduce the bacterial
load on skin surfaces surrounding the eyes, thus addressing the
underlying cause of bacterial dry eye. Both Avenova and Zocular
at-home products are completely safe for regular use.”
Zocular products include easy-to-use in-office and at-home
treatment options. The ZocuKit for ZEST® (Zocular Eyelid System
Technology) is a 10-minute, in-office procedure clinically proven
to provide dramatic, immediate and lasting results for patients
suffering from dry eye. ZEST requires no capital equipment or
topical anesthetic, and is well tolerated by patients. At-home
consumer dry eye maintenance products include ZocuWipe™, a
once-daily disposable towel that neutralizes and removes oil, dirt
and debris; ZocuFoam™, a gentle eyelid cleansing and moisturizing
foam; and ZocuShield™, an easy-to-apply gel-filled syringe.
“As a dry eye sufferer myself, one of the biggest problems is
the time required for any treatment to produce results. We at Okra
Limited pioneered the use of natural okra polysaccharides to solve
this unmet need – the ability to deliver immediate and durable
clinical improvement within minutes to patients with ocular surface
problems,” said Dr. Pham. “Linking the Zokrex polysaccharide
technology in Zocular products with Avenova’s pharmaceutical-grade
hypochlorous acid provides unmatched treatment efficacy for almost
any clinical situation. Our team at Okra is delighted to partner
with NovaBay to put this powerful combination of products in the
hands of eyecare specialists.”
To learn more about Zocular and to order products, eyecare
specialists are invited to call 844-ZOCULAR.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on high-quality, differentiated, anti-infective consumer
products: Avenova®, the premier antimicrobial lid and lash spray,
CelleRx® Clinical Reset™, a breakthrough product in the beauty
category, and NeutroPhase® Skin and Wound Cleanser for wound
healing. NovaBay’s products are formulated with its patented, pure,
stable, pharmaceutical-grade hypochlorous acid that replicates the
antimicrobial chemicals used by white blood cells to fight
infection. NovaBay’s hypochlorous acid products do not cause
stinging or irritation, are non‑toxic and non-sensitizing, making
them completely safe for regular use. Avenova is the only
commercial hypochlorous acid lid and lash spray product clinically
proven to reduce bacterial load on ocular skin surfaces, thus
effectively addressing the underlying cause of bacterial dry
eye.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward‑looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our current
product offerings and marketing efforts, the financial impact of
our partnerships, and any future revenue that may result from
selling these products, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings with the
Securities and Exchange Commission, especially under the heading
“Risk Factors.” The forward-looking statements in this release
speak only as of this date, and NovaBay disclaims any intent or
obligation to revise or update publicly any forward-looking
statement except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210819005141/en/
NovaBay Contacts:
At the Company Justin Hall Chief
Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investors LHA Investor Relations
Jody Cain 310-691-7100 jcain@lhai.com
Okra LLC Contact: Peter Pham, MD Chief Executive Officer
844-962-8527 peter.pham@zocular.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024